The global generic drugs market size is estimated to grow from USD 439.37 billion in 2022 to lead an estimated value of USD 738.53 billion by 2032 at an expanding CAGR of 5.3% from 2023 to 2032.
The global generic drugs market size is estimated to grow from USD 439.37 billion in 2022 to lead an estimated value of USD 738.53 billion by 2032 at an expanding CAGR of 5.3% from 2023 to 2032.
The global generic drugs market is projected to surpass around USD 637.66 billion by 2029, as a result of rising generic drug approvals and increased overall funding in the generic drugs industry.
Download a short version of this report @ https://www.towardshealthcare.com/personalized-scope/5053
Driving Healthcare Cost Savings: The Decline of Generic Drug Expenditure
The generic drugs market, encompassing pharmaceuticals bioequivalent to brand-name drugs, serves as a cornerstone for affordable and accessible medications worldwide. With over 10,000 FDA-approved generic drugs, these alternatives constitute more than 90% of dispensed prescriptions in the U.S., while only accounting for 18% of overall spending.
Key drivers include the expiration of brand-name drug patents, fostering competition, and subsequently, reduced drug prices.
According to ASPE, retail generic drug expenditures consistently declined between 2016 and 2021, signaling a shift in spending patterns. In the U.S., despite constituting only 3% of total healthcare spending, generic drugs deliver significant cost savings. In 2021, the average copay for generic drugs was $6.16, compared to $56.12 for brand-name drugs, emphasizing their crucial role in healthcare cost management.
Key Drivers of Generic Drug Market: Patents, Competition, and Affordability
- Patent Expirations: The expiration of patents on brand-name drugs creates an entry point for generic alternatives, fostering competition and driving down drug prices.
- Cost Savings: Generic drugs, comprising 93% with a copay below $20, offer substantial cost savings compared to brand-name drugs. This affordability enhances accessibility and aids in healthcare cost management.
- Off-Patent, Off-Exclusivity Drugs: These drugs, losing patent protection or exclusivity, contribute to increased competition, accessibility, and cost-effectiveness. The FDA's transparent list of such drugs promotes market competition and innovation.
Customize this study as per your requirement @ https://www.towardshealthcare.com/customization/5053
Crucial Role of Off-Patent, Off-Exclusivity Drugs: Enhancing Access and Affordability
Off-patent and off-exclusivity drugs, post-patent protection loss, play a vital role in the generic drugs market. By promoting competition, affordability, and treatment access, these drugs offer cost savings for patients and healthcare systems. Priced lower than brand-name counterparts, they contribute to sustainable healthcare systems, providing accessible and affordable treatment options while maintaining quality and therapeutic efficacy. The availability of generic versions of these drugs enhances treatment options, improves patient outcomes, and supports the overarching goal of accessible and affordable healthcare.
Increasing Generic Drug Approvals Augment the Market Growth
The generic drugs market is experiencing a significant boost due to the rising number of product approvals. Generic drugs are pharmaceutical products that are bioequivalent to brand-name drugs, providing the same therapeutic effects at a lower cost. The increasing approvals of generic drugs offer several advantages and opportunities for both patients and the pharmaceutical industry.
You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com
Regional Overview of the Generic Drugs Market
The generic drugs market in North America, particularly in the United States, is a significant and thriving industry. The United States has been a key player in the global generic drugs market, accounting for a substantial share of the market revenue. In 2021, a total of 6.4 billion prescriptions were dispensed to patients in the United States.
It is noteworthy that 91% of these prescriptions were for generic and biosimilar medicines, which are more affordable alternatives to brand-name drugs. The utilization of these lower-cost medications resulted in substantial cost savings amounting to $373 billion for various stakeholders, including patients, consumers, employers, and taxpayers. This emphasizes the significant role that generic medicines play in improving the accessibility and affordability of healthcare in the United States.
Explore the comprehensive statistics and insights on healthcare industry data and its associated segmentation: Get a Subscription
In the U.S., generic pharmaceutical companies are responsible for manufacturing the medicines used in 9 out of 10 prescriptions that are dispensed. This highlights the significant role played by generic drugs in providing accessible and affordable healthcare options to the population. The U.S. healthcare system encourages the use of generic drugs through various policies and initiatives. For example, the U.S. Food and Drug Administration (FDA) has implemented programs to expedite the review and approval process for generic drugs, such as the Generic Drug User Fee Amendments (GDUFA).
These programs aim to increase competition, reduce drug prices, and enhance the availability of generic drugs to patients. In addition, in 2021, the top 10 best generics played a crucial role in cost savings, totaling $110 billion. These generics are affordable alternatives to brand-name drugs and have significantly contributed to reducing healthcare expenses. Furthermore, the ten generics with the highest sales volume in 2021 accounted for substantial savings of $66 billion.
The generic drugs market in the Asia Pacific region is experiencing significant growth and presents lucrative opportunities for pharmaceutical companies. Several factors contribute to the expansion of the generic drugs market in this region. India has emerged as a leading provider of generic medicines on a global scale. With a significant 20% share in the global supply, India manufactures around 60,000 different generic brands across 60 therapeutic categories.
Competitive Landscape
Some of the prominent players involved in the generic drugs market are Mylan N.V., Abbott Laboratories, ALLERGAN, Teva Pharmaceutical Industries Ltd., Eli Lilly and Company, STADA Arzneimittel AG, GlaxoSmithKline Plc., Baxter International Inc., Pfizer Inc., and Sandoz International GmbH.
Browse More Insights of Towards Healthcare:
- The global brain implants market surpassed USD 5.85 billion in 2022 and is projected to hit around USD 14.24 billion by 2032, growing at a CAGR of 9.3% from 2023 to 2032.
- The non-invasive blood glucose monitoring system market is estimated to grow from USD 21.76 million in 2022, to reach an estimated USD 202.73 million by 2032 at CAGR of 25.0% 2023-2032.
- The global diabetes drugs market to reach an estimated USD 118 billion by 2032 and is estimated to grow from USD 61.87 billion in 2022 at CAGR of 6.7% for 2023-2032.
- The global antibodies drug market size reached USD 200.18 billion in 2022 and is expected to exceed USD 605.8 billion by 2032, expanding at a CAGR of 10.8% between 2023 and 2032.
- The global non-oncology precision medicine market size reached USD 70.16 billion in 2022 and is estimated to surpass around USD 163.5 billion by 2032, expanding at a CAGR of 8.7% from 2023 to 2032.
Strengths:
- Market players in the generic drugs industry often have a wide range of products across various therapeutic areas, allowing them to cater to diverse patient needs.
- Many market players have robust manufacturing facilities and processes that ensure the efficient production of high-quality generic drugs at competitive prices.
Weaknesses:
- Market players in the generic drugs industry face challenges related to limited patent exclusivity, as they cannot rely on exclusive rights to market their products. This makes competition intense and margins relatively low.
- Compared to branded drugs, generic drugs may have lower brand recognition, which can make it more challenging for market players to establish a strong market presence and differentiate themselves from Competitors.
Opportunities:
- The rising healthcare costs and the need for affordable treatment options present significant opportunities for market players in the generic drugs industry.
- As the global population continues to age, there is a growing need for medications to treat age-related diseases, creating a larger market for generic drugs.
Threats:
- The generic drugs market is highly competitive, with numerous players vying for market share. This can lead to price pressures and margin erosion for individual market players.
- Market players must navigate complex regulatory frameworks, including obtaining approvals and adhering to strict quality standards, which can be time-consuming and costly.
Market Segmentation
By Brand
- Pure generic drugs
- Branded generic drugs
By Route of Drug Administration
- Oral
- Topical
- Parental
- Others
By Therapeutic Application
- Central nervous system (CNS)
- Cardiovascular
- Dermatology
- Oncology
- Respiratory
- Others
By Key Distribution Channel
- Hospitals Pharmacies
- Retail Pharmacies
- Others
By Geography
- North America
- U.S.
- Canada
- Europe
- U.K.
- Germany
- France
- Asia-Pacific
- China
- India
- Japan
- South Korea
- Malaysia
- Philippines
- Latin America
- Brazil
- Rest of Latin America
- Middle East & Africa (MEA)
- GCC
- North Africa
- South Africa
- Rest of the Middle East & Africa
You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com
Explore the comprehensive statistics and insights on healthcare industry data and its associated segmentation: Get a Subscription
About Us
Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations. We are a global strategy consulting firm that assists business leaders in gaining a competitive edge and accelerating growth. We are a provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations.
Web: https://www.towardshealthcare.com
Browse our Brand-New Journal@ https://www.towardspackaging.com
Browse our Consulting Website@ https://www.precedenceresearch.com
For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare